-
-
-
-
-
-
-
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
-
-
-
-
-
-
-
Lisata Therapeutics (LSTA) Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial
-
-
-
-
-
-
-
Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
-
-
-
-
-
-
-
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
-
-
-
1,155,000 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

